Pooled procurement and voluntary licensing for essential cancer medicines in low-income countries
Buy essential cancer drugs for many countries at once and license newer ones to generic makers, as was done for HIV, so prices fall to what those health systems can pay.
HIV treatment reached tens of millions because the Medicines Patent Pool, pooled procurement and tiered pricing lowered costs by over 90%. Cancer has partial efforts (the ATOM Coalition, pooled tenders for childhood cancer drugs) but no comprehensive mechanism. The proposal is a cancer medicines pool: voluntary licences from originators for defined territories on a core list (trastuzumab, imatinib, pembrolizumab or biosimilar checkpoint inhibitors, and generics with supply problems), pooled multi-country tenders, quality assurance and supply security, financed with development bank guarantees.
- Most of the world has almost no cancer care · Seven in ten cancer deaths happen in low- and middle-income countries, where radiotherapy, pathology, surgery and drugs are scarce.
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.
Pages like this
not linked directly; found by shared links- IdeaTie WHO essential-medicines listing to a published tiered price and supply pledge
Shares Imatinib, Trastuzumab, Prices and value, Most of the world has almost no cancer care.
- IdeaPooled international procurement of essential adult cancer medicines
Shares Imatinib, Trastuzumab, Prices and value, Most of the world has almost no cancer care.
- IdeaMedicines Patent Pool licences for every patented cancer drug on the WHO list
Shares Imatinib, Prices and value, Most of the world has almost no cancer care.
- IdeaSubscription pricing for checkpoint inhibitors: fixed national fee, unlimited use
Shares Prices and value, Most of the world has almost no cancer care, Pembrolizumab.
- IdeaA joint price negotiation bloc for middle-income countries, modelled on Beneluxa
Shares Prices and value, Most of the world has almost no cancer care.
- IdeaBuy out the patent on a curative cancer drug and sell it at generic prices
Shares Prices and value, Most of the world has almost no cancer care.
- IdeaGrant extra exclusivity only in exchange for binding low prices in poorer countries
Shares Prices and value, Most of the world has almost no cancer care.
- InstitutionCentral Drugs Standard Control Organization
Shares Imatinib, Trastuzumab, Prices and value, Most of the world has almost no cancer care.